Vigonvita
2630.HKSuzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile2630.HK · Stock Price
HKD 79.95-5.95 (-6.93%)
Market Cap: $680.8M
Historical price data
Overview
A Chinese biopharma company with a fully integrated platform developing and commercializing drugs for viral infections, neuropsychiatry, and reproductive health.
Infectious DiseaseNeurologyPsychiatryUrology/Reproductive Health
Technology Platform
A fully integrated, internally controlled drug development and manufacturing platform covering lead discovery, preclinical and clinical research, GMP production, and commercialization, with a specialized focus on small molecule therapeutics.
Opportunities
Growth opportunities include geographic expansion into North Africa, Central Asia, the Middle East, and Russia via its Uzbekistan subsidiary, label expansion of VV116 into other viral indications like RSV, and advancing its neurology/psychiatry pipeline (LV232, VV119) which addresses large, chronic markets.
Risk Factors
Key risks include dependence on VV116 in a post-pandemic market with evolving demand, intense competition in the erectile dysfunction market for TPN171, clinical and regulatory uncertainty for its early- to mid-stage pipeline, and execution risks associated with international expansion.
Competitive Landscape
In antivirals, VV116 competes with other oral COVID-19 therapies like Paxlovid; its differentiation includes a nucleoside analog mechanism and a clean genotoxicity profile. TPN171 faces competition from established PDE5 inhibitors (sildenafil, tadalafil); its novelty and high selectivity are its key claimed differentiators.